ArticleRespiratory research2026
Distinct anti-MDA5 antibody trajectories associated with long-term outcomes in 6-month survivors of anti-MDA5 dermatomyositis with interstitial lung disease.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundsAnti-MDA5 antibody-positive dermatomyositis (DM) is characterized by the presence of anti-MDA5 antibodies. We aimed to assess longitudinal changes of anti-MDA5 antibody levels and long-term outcomes in 6-month survivors of anti-MDA5 + DM with interstitial lung disease (ILD).
methodsAnti-MDA5 antibody titers were measured using enzyme-linked immunosorbent assay upon newly diagnosed anti-MDA5 + DM-ILD patients. Patients with follow-up beyond 6 months and at least two anti-MDA5 antibody measurements were subsequently subjected to group-based trajectory analysis by utilizing latent class mixture model. Seroconversion was defined as a change from positive to negative for anti-MDA5 antibodies. Outcome measurements include low disease activity (LDA) status and remission.
findingsIn 6-month survivors, two anti-MDA5 antibody trajectories were identified: "fast seroconvertors" and "slow seroconvertors". The median time to anti-MDA5 seroconversion for fast seroconvertors was 9 (IQR: 5-15) months, whereas slow seroconvertors did not achieve 50% anti-MDA5 seroconversion during the follow-up period. Although with a lower baseline PaO
conclusionsTwo distinct trajectories of anti-MDA5 antibody levels among 6-month survivors with anti-MDA5 + DM-ILD have been identified. The long-term outcomes were favorable for those with fast seroconvertors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.